Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market
The stock's rise snapped a four-day losing streak.
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug
Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...
Vertex Pharmaceuticals gets CHMP opinion recommending Kaftrio label expansion
Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $408.00
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $407.00 to $408.00 ...
BioSpace1d
Vertex Severs Liver Gene Therapies Partnership With Verve
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
Is Vertex Pharmaceuticals Gaining or Losing Market Support?
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
Vertex Pharmaceuticals upgraded to Buy from Hold at Erste Group
Erste Group upgraded Vertex Pharmaceuticals (VRTX) to Buy from Hold. The firm expects the company to “develop positively in the coming quarters ...
Vertex Pharmaceuticals Incorporated (VRTX): Among Renaissance Technologies Portfolio’s Top Stock Picks
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
BioSpace5d
Vertex’s Journavx Changes the Pain Treatment Landscape But Opioids Here to Stay
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
Sionna Therapeutics’ IPO: A strategic shift in the cystic fibrosis market
Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling ...
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years
Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a ...